Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

W.F. YOUNG's OTC CHLOROXYLENOL EFFICACY IN TINEA PEDIS

Executive Summary

W.F. YOUNG's OTC CHLOROXYLENOL EFFICACY IN TINEA PEDIS has been demonstrated in a double-blind placebo controlled study of 58 patients, the firm maintained in a recent submission to FDA. The company reported that "84.6% of those subjects on active medication were cured," while 15.8% of those in the placebo group were cured. "At the 99.9% confidence level," the company said, "there was a significant difference between the active and placebo groups." W.F. Young explained that each subject applied 2% chloroxylenol or placebo to affected areas twice daily for 28 days. After two weeks, subjects were subjectively evaluated by the investigator for clinical signs and symptoms of athlete's foot. After an additional two weeks subjects were clinically evaluated, at which time skin scrapings were collected, a KOH preparation made, and culture performed. Subjects then went through a two week period without medication. At the end of the six week study subjects were further evaluated. A cure was defined as complete resolution of clinical signs and symptoms, a negative KOH and a negative culture. FDA's OTC Antimicrobial II Panel placed chloroxylenol in Category III and recommended that one double-blind placebo controlled clinical trial was necessary to establish efficacy of the product. The company noted anecdotally that four of the subjects also had onychomycosis, a fungal infection of the toenail. "In addition to evaluating the efficacy of [chloroxylenol] for athlete's foot, the subject's response to the product was evaluated vis-a-vis their toenail disease," W. F. Young stated. "Although no formal conclusion can be reached regarding this issue, it was the subjective impression that subjects were, in fact, responding to treatment of their toenails if the product given was also curing their athlete's foot."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS006587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel